Video

PCa focal therapy: Who are the best candidates?

In this video, Scott Eggener, MD, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.

In this video, Scott Eggener, MD, of the University of Chicago, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.

 

More videos from Urology Times:

Study will test targeted PCa therapies based on genomic alterations

LUGPA President Dr. Richard Harris: 2020 challenges

Dr. Mara Holton discusses LUGPA's recent policy victories, upcoming challenges

Related Videos
Amy Pearlman, MD, answers a question during a video interview
Team of surgeons | Image Credit: © shefkate - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Marah C. Hehemann, MD, answers a question during a video interview
Crop shot of senior man sitting on sofa with doctor during home visit taking notes on clipboard | Image Credit: © DragonImages - stock.adobe.com
Olivia Paulsen answers a question during a video interview
Related Content
Healthy diet may lower risk of grade reclassification in patients with GG1 prostate cancer
October 24th 2024

Healthy diet may lower risk of grade reclassification in patients with GG1 prostate cancer

Hannah Clarke
Patients with higher baseline HEI and E-HEI scores were less likely to experience grade reclassification.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
PACE-B trial: Five-fraction SBRT noninferior to conventional radiotherapy in prostate cancer
October 17th 2024

PACE-B trial: Five-fraction SBRT noninferior to conventional radiotherapy in prostate cancer

Hannah Clarke
At 5 years, 95.8% of patients in the SBRT arm were free from biochemical or clinical failure compared with 94.6% of patients in the control radiotherapy arm.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
October 14th 2024

Lisa F. Newcomb, PhD, on active surveillance for prostate cancer

Lisa F. Newcomb, PhD
"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the risk-benefit of PSA screening," says Lisa F. Newcomb, PhD.
Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer
October 11th 2024

Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer

Hannah Clarke
“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.
© 2024 MJH Life Sciences

All rights reserved.